Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 4/2012

Open Access 01-08-2012 | Original Paper

CSE1L, DIDO1 and RBM39 in colorectal adenoma to carcinoma progression

Authors: Anke H. Sillars-Hardebol, Beatriz Carvalho, Jeroen A.M. Beliën, Meike de Wit, Pien M. Delis-van Diemen, Marianne Tijssen, Mark A. van de Wiel, Fredrik Pontén, Gerrit A. Meijer, Remond J. A. Fijneman

Published in: Cellular Oncology | Issue 4/2012

Login to get access

Abstract

Background

Gain of chromosome 20q is an important factor in the progression from colorectal adenomas to carcinomas. Genes that drive 20q gain are expected to show correlation of mRNA and protein expression levels with 20q DNA copy number status while functionally influencing cancer processes. CSE1L, DIDO1 and RBM39 are located on the 20q amplicon and affect processes such as cell viability and anchorage-independent growth in colorectal cancer. This study aimed to investigate whether CSE1L, DIDO1 and RBM39 may drive 20q amplification.

Methods

Protein expression levels were examined by immunohistochemical evaluation of tissue microarrays containing a series of colorectal adenoma and carcinoma samples, which were characterized by genome-wide (microarray-based) DNA and mRNA profiling.

Results

CSE1L, DIDO1 and RBM39 mRNA expression levels correlated with chromosome 20q DNA copy number status. CSE1L protein expression was not associated with 20q gain, although its expression was increased in carcinomas compared to adenomas. DIDO1 and RBM39 protein expression was quite strong in the majority of tumors irrespective of 20q DNA copy number status.

Conclusion

The lack of correlation between protein expression levels and 20q DNA copy number status implies that CSE1L, DIDO1 and RBM39 are merely passengers rather than drivers of chromosome 20q gain in colorectal adenoma-to-carcinoma progression.
Appendix
Available only for authorised users
Literature
1.
A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, M.J. Thun, Cancer statistics, 2009. CA Cancer J. Clin. 59, 225 (2009)PubMedCrossRef
2.
H. Shinya, W.I. Wolff, Morphology, anatomic distribution and cancer potential of colonic polyps. Ann. Surg. 190, 679 (1979)PubMedCrossRef
3.
4.
A. Esquela-Kerscher, F.J. Slack, Oncomirs—microRNAs with a role in cancer. Nat. Rev. Cancer 6, 259 (2006)PubMedCrossRef
5.
A.H. Sillars-Hardebol, B. Carvalho, M. van Engeland, R.J. Fijneman, G.A. Meijer, The adenoma hunt in colorectal cancer screening: defining the target. J. Pathol. 226, 1 (2012)PubMedCrossRef
6.
P.M. De Angelis, O.P. Clausen, A. Schjolberg, T. Stokke, Chromosomal gains and losses in primary colorectal carcinomas detected by CGH and their associations with tumour DNA ploidy, genotypes and phenotypes. Br. J. Cancer 80, 526 (1999)PubMedCrossRef
7.
B. Carvalho, C. Postma, S. Mongera, E. Hopmans, S. Diskin, M.A. van de Wiel, W. van Criekinge, O. Thas, A. Matthai, M.A. Cuesta, J.S. Terhaar Sive Droste, M. Craanen, E. Schrock, B. Ylstra, G.A. Meijer, Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression. Gut 58, 79 (2009)PubMedCrossRef
8.
C. Postma, S. Terwischa, M.A. Hermsen, J.R. van der Sijp, G.A. Meijer, Gain of chromosome 20q is an indicator of poor prognosis in colorectal cancer. Cell. Oncol. 29, 73 (2007)PubMed
9.
A.H. Sillars-Hardebol, B. Carvalho, M. Tijssen, J.A. Belien, M. de Wit, P.M. Delis-van Diemen, F. Ponten, M.A. van de Wiel, R.J. Fijneman, G.A. Meijer, TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression. Gut doi:10.​1136/​gutjnl-2011-301153 (Epub ahead of print)
10.
P. Platzer, M.B. Upender, K. Wilson, J. Willis, J. Lutterbaugh, A. Nosrati, J.K. Willson, D. Mack, T. Ried, S. Markowitz, Silence of chromosomal amplifications in colon cancer. Cancer Res. 62, 1134 (2002)PubMed
11.
M. de Wit, C.R. Jimenez, B. Carvalho, J.A. Belien, P.M. Delis-van Diemen, S. Mongera, S.R. Piersma, M. Vikas, S. Navani, F. Ponten, G.A. Meijer, R.J. Fijneman, Cell surface proteomics identifies glucose transporter type 1 and prion protein as candidate biomarkers for colorectal adenoma-to-carcinoma progression. Gut 61, 855 (2012)PubMedCrossRef
12.
M. Uhlen, E. Bjorling, C. Agaton, C.A. Szigyarto, B. Amini, E. Andersen, A.C. Andersson, P. Angelidou, A. Asplund, C. Asplund, L. Berglund, K. Bergstrom, H. Brumer, D. Cerjan, M. Ekstrom, A. Elobeid, C. Eriksson, L. Fagerberg, R. Falk, J. Fall, M. Forsberg, M.G. Bjorklund, K. Gumbel, A. Halimi, I. Hallin, C. Hamsten, M. Hansson, M. Hedhammar, G. Hercules, C. Kampf, K. Larsson, M. Lindskog, W. Lodewyckx, J. Lund, J. Lundeberg, K. Magnusson, E. Malm, P. Nilsson, J. Odling, P. Oksvold, I. Olsson, E. Oster, J. Ottosson, L. Paavilainen, A. Persson, R. Rimini, J. Rockberg, M. Runeson, A. Sivertsson, A. Skollermo, J. Steen, M. Stenvall, F. Sterky, S. Stromberg, M. Sundberg, H. Tegel, S. Tourle, E. Wahlund, A. Walden, J. Wan, H. Wernerus, J. Westberg, K. Wester, U. Wrethagen, L.L. Xu, S. Hober, F. Ponten, A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol. Cell Proteomics. 4, 1920 (2005)PubMedCrossRef
13.
M. Uhlen, P. Oksvold, L. Fagerberg, E. Lundberg, K. Jonasson, M. Forsberg, M. Zwahlen, C. Kampf, K. Wester, S. Hober, H. Wernerus, L. Bjorling, F. Ponten, Towards a knowledge-based Human Protein Atlas. Nat. Biotechnol. 28, 1248 (2010)PubMedCrossRef
14.
U. Brinkmann, E. Brinkmann, M. Gallo, I. Pastan, Cloning and characterization of a cellular apoptosis susceptibility gene, the human homologue to the yeast chromosome segregation gene CSE1. Proc. Natl. Acad. Sci. U. S. A. 92, 10427 (1995)PubMedCrossRef
15.
U. Brinkmann, E. Brinkmann, M. Gallo, U. Scherf, I. Pastan, Role of CAS, a human homologue to the yeast chromosome segregation gene CSE1, in toxin and tumor necrosis factor mediated apoptosis. Biochemistry 35, 6891 (1996)PubMedCrossRef
16.
U. Brinkmann, CAS, the human homologue of the yeast chromosome-segregation gene CSE1, in proliferation, apoptosis, and cancer. Am. J. Hum. Genet. 62, 509 (1998)PubMedCrossRef
17.
A. Wellmann, L. Krenacs, T. Fest, U. Scherf, I. Pastan, M. Raffeld, U. Brinkmann, Localization of the cell proliferation and apoptosis-associated CAS protein in lymphoid neoplasms. Am. J. Pathol. 150, 25 (1997)PubMed
18.
Z. Xiao, J.T. McGrew, A.J. Schroeder, M. Fitzgerald-Hayes, CSE1 and CSE2, two new genes required for accurate mitotic chromosome segregation in Saccharomyces cerevisiae. Mol. Cell. Biol. 13, 4691 (1993)PubMed
19.
C.F. Liao, S.F. Luo, L.T. Li, C.Y. Lin, Y.C. Chen, M.C. Jiang, CSE1L/CAS, the cellular apoptosis susceptibility protein, enhances invasion and metastasis but not proliferation of cancer cells. J. Exp. Clin. Cancer Res. 27, 15 (2008)PubMedCrossRef
20.
C.J. Tai, S.C. Shen, W.R. Lee, C.F. Liao, W.P. Deng, H.Y. Chiou, C.I. Hsieh, J.N. Tung, C.S. Chen, J.F. Chiou, L.T. Li, C.Y. Lin, C.H. Hsu, M.C. Jiang, Increased cellular apoptosis susceptibility (CSE1L/CAS) protein expression promotes protrusion extension and enhances migration of MCF-7 breast cancer cells. Exp. Cell Res. 316, 2969 (2010)PubMedCrossRef
21.
U. Brinkmann, M. Gallo, M.H. Polymeropoulos, I. Pastan, The human CAS (cellular apoptosis susceptibility) gene mapping on chromosome 20q13 is amplified in BT474 breast cancer cells and part of aberrant chromosomes in breast and colon cancer cell lines. Genome Res. 6, 187 (1996)PubMedCrossRef
22.
A.B. Hui, K.W. Lo, P.M. Teo, K.F. To, D.P. Huang, Genome wide detection of oncogene amplifications in nasopharyngeal carcinoma by array based comparative genomic hybridization. Int. J. Oncol. 20, 467 (2002)PubMed
23.
C.Y. Tong, A.B. Hui, X.L. Yin, J.C. Pang, X.L. Zhu, W.S. Poon, H.K. Ng, Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization. J. Neurosurg. 100, 187 (2004)PubMed
24.
H. Brustmann, Expression of cellular apoptosis susceptibility protein in serous ovarian carcinoma: a clinicopathologic and immunohistochemical study. Gynecol. Oncol. 92, 268 (2004)PubMedCrossRef
25.
K. Shiraki, K. Fujikawa, K. Sugimoto, T. Ito, T. Yamanaka, M. Suzuki, K. Yoneda, K. Sugimoto, K. Takase, T. Nakano, Cellular apoptosis susceptibility protein and proliferation in human hepatocellular carcinoma. Int. J. Mol. Med. 18, 77 (2006)PubMed
26.
I.M. Seiden-Long, K.R. Brown, W. Shih, D.A. Wigle, N. Radulovich, I. Jurisica, M.S. Tsao, Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer. Oncogene 25, 91 (2006)PubMed
27.
A. Wellmann, P. Flemming, P. Behrens, K. Wuppermann, H. Lang, K. Oldhafer, I. Pastan, U. Brinkmann, High expression of the proliferation and apoptosis associated CSE1L/CAS gene in hepatitis and liver neoplasms: Correlation with tumor progression. Int. J. Mol. Med. 7, 489 (2001)PubMed
28.
P. Behrens, U. Brinkmann, F. Fogt, N. Wernert, A. Wellmann, Implication of the proliferation and apoptosis associated CSE1L/CAS gene for breast cancer development. Anticancer. Res. 21, 2413 (2001)PubMed
29.
G. Peiro, J. Diebold, G.B. Baretton, R. Kimmig, U. Lohrs, Cellular apoptosis susceptibility gene expression in endometrial carcinoma: Correlation with Bcl-2, Bax, and caspase-3 expression and outcome. Int. J. Gynecol. Pathol. 20, 359 (2001)PubMedCrossRef
30.
T.R. Kau, J.C. Way, P.A. Silver, Nuclear transport and cancer: From mechanism to intervention. Nat. Rev. Cancer 4, 106 (2004)PubMedCrossRef
31.
U. Kutay, F.R. Bischoff, S. Kostka, R. Kraft, D. Gorlich, Export of importin alpha from the nucleus is mediated by a specific nuclear transport factor. Cell 90, 1061 (1997)PubMedCrossRef
32.
K.S. Ullman, M.A. Powers, D.J. Forbes, Nuclear export receptors: From importin to exportin. Cell 90, 967 (1997)PubMedCrossRef
33.
K.M. Ryan, A.C. Phillips, K.H. Vousden, Regulation and function of the p53 tumor suppressor protein. Curr. Opin. Cell Biol. 13, 332 (2001)PubMedCrossRef
34.
W.C. Uen, C.J. Tai, S.C. Shen, W.R. Lee, T.Y. Tsao, W.P. Deng, H.Y. Chiou, C.H. Hsu, C.I. Hsieh, C.F. Liao, M.C. Jiang, Differential distributions of CSE1L/CAS and E-cadherin in the polarized and non-polarized epithelial glands of neoplastic colorectal epithelium. J. Mol. Histol. 41, 259 (2010)PubMedCrossRef
35.
C.S. Stella Tsai, H.C. Chen, J.N. Tung, S.S. Tsou, T.Y. Tsao, C.F. Liao, Y.C. Chen, C.Y. Yeh, K.T. Yeh, M.C. Jiang, Serum cellular apoptosis susceptibility protein is a potential prognostic marker for metastatic colorectal cancer. Am. J. Pathol. 176, 1619 (2010)PubMedCrossRef
36.
T.Y. Tsao, C.S. Tsai, J.N. Tung, S.L. Chen, C.H. Yue, C.F. Liao, C.C. Wang, M.C. Jiang, Function of CSE1L/CAS in the secretion of HT-29 human colorectal cells and its expression in human colon. Mol. Cell. Biochem. 327, 163 (2009)PubMedCrossRef
37.
R.J. Fijneman, M. de Wit, M. Pourghiasian, S.R. Piersma, T.V. Pham, M.O. Warmoes, M. Lavaei, C. Piso, F. Smit, P.M. Delis-van Diemen, S.T. van Turenhout, J.S.Terhaar sive Droste, C.J. Mulder, M.A. Blankenstein, E.C. Robanus-Maandag, R. Smits, R. Fodde, V.W. van Hinsbergh, G.A. Meijer, C.R. Jimenez, Proximal fluid proteome profiling of mouse colon tumors reveals biomarkers for early diagnosis of human colorectal cancer. Clin. Cancer Res. 18, 2613 (2012)PubMedCrossRef
38.
U. Scherf, I. Pastan, M.C. Willingham, U. Brinkmann, The human CAS protein which is homologous to the CSE1 yeast chromosome segregation gene product is associated with microtubules and mitotic spindle. Proc. Natl. Acad. Sci. U. S. A. 93, 2670 (1996)PubMedCrossRef
39.
A.H. Sillars-Hardebol, B. Carvalho, M. de Wit, C. Postma, P.M. Delis-van Diemen, S. Mongera, B. Ylstra, M.A. van de Wiel, G.A. Meijer, R.J. Fijneman, Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression. Tumour. Biol. 31, 89 (2010)PubMedCrossRef
40.
D. Garcia-Domingo, D. Ramirez, G. Gonzalez de Buitrago, A. Martinez, Death inducer-obliterator 1 triggers apoptosis after nuclear translocation and caspase upregulation. Mol. Cell. Biol. 23, 3216 (2003)PubMedCrossRef
41.
V. Trachana, K.H. van Wely, A.A. Guerrero, A. Futterer, A. Martinez, Dido disruption leads to centrosome amplification and mitotic checkpoint defects compromising chromosome stability. Proc. Natl. Acad. Sci. U. S. A. 104, 2691 (2007)PubMedCrossRef
42.
A.M. Rojas, L. Sanchez-Pulido, A. Futterer, K.H. van Wely, A. Martinez, A. Valencia, Death inducer obliterator protein 1 in the context of DNA regulation. Sequence analyses of distant homologues point to a novel functional role. FEBS J. 272, 3505 (2005)PubMedCrossRef
43.
D.J. Jung, S.Y. Na, D.S. Na, J.W. Lee, Molecular cloning and characterization of CAPER, a novel coactivator of activating protein-1 and estrogen receptors. J. Biol. Chem. 277, 1229 (2002)PubMedCrossRef
44.
D.H. Dowhan, E.P. Hong, D. Auboeuf, A.P. Dennis, M.M. Wilson, S.M. Berget, B.W. O’Malley, Steroid hormone receptor coactivation and alternative RNA splicing by U2AF65-related proteins CAPERalpha and CAPERbeta. Mol. Cell 17, 429 (2005)PubMedCrossRef
45.
A. Srebrow, A.R. Kornblihtt, The connection between splicing and cancer. J. Cell Sci. 119, 2635 (2006)PubMedCrossRef
46.
J.P. Venables, Unbalanced alternative splicing and its significance in cancer. Bioessays 28, 378 (2006)PubMedCrossRef
47.
M.J. Moore, Q. Wang, C.J. Kennedy, P.A. Silver, An alternative splicing network links cell-cycle control to apoptosis. Cell 142, 625 (2010)PubMedCrossRef
48.
C.S. Bangur, A. Switzer, L. Fan, M.J. Marton, M.R. Meyer, T. Wang, Identification of genes over-expressed in small cell lung carcinoma using suppression subtractive hybridization and cDNA microarray expression analysis. Oncogene 21, 3814 (2002)PubMedCrossRef
49.
I. Mercier, M.C. Casimiro, J. Zhou, C. Wang, C. Plymire, K.G. Bryant, K.M. Daumer, F. Sotgia, G. Bonuccelli, A.K. Witkiewicz, J. Lin, T.H. Tran, J. Milliman, P.G. Frank, J.F. Jasmin, H. Rui, R.G. Pestell, M.P. Lisanti, Genetic ablation of caveolin-1 drives estrogen-hypersensitivity and the development of DCIS-like mammary lesions. Am. J. Pathol. 174, 1172 (2009)PubMedCrossRef
Metadata
Title
CSE1L, DIDO1 and RBM39 in colorectal adenoma to carcinoma progression
Authors
Anke H. Sillars-Hardebol
Beatriz Carvalho
Jeroen A.M. Beliën
Meike de Wit
Pien M. Delis-van Diemen
Marianne Tijssen
Mark A. van de Wiel
Fredrik Pontén
Gerrit A. Meijer
Remond J. A. Fijneman
Publication date
01-08-2012
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 4/2012
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-012-0088-2

Other articles of this Issue 4/2012

Cellular Oncology 4/2012 Go to the issue

Original Paper

miR-15a/16-1 influences BCL2 expression in keratocystic odontogenic tumors

Original Paper

Hypomethylation of LINE-1, and not centromeric SAT-α, is associated with centromeric instability in head and neck squamous cell carcinoma

Original Paper

Analytical sensitivity and stability of DNA methylation testing in stool samples for colorectal cancer detection

Review

DNA hypermethylation biomarkers to predict response to cisplatin treatment, radiotherapy or chemoradiation: the present state of art

Original Paper

Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours

Original Paper

Myrtenal attenuates diethylnitrosamine-induced hepatocellular carcinoma in rats by stabilizing intrinsic antioxidants and modulating apoptotic and anti-apoptotic cascades
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits